Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis
Conclusions:
Unlike other smoking cessation medications, varenicline demonstrated greater efficacy among women smokers for short and immediate-term outcomes and equal efficacy for 1-year outcomes. Varenicline may be particularly useful for reducing the sex disparity typically seen in rates of smoking cessation.
Implications:
Varenicline is currently the most effective FDA-approved smoking cessation medication and this is the first demonstration that women compared with men have a preferred therapeutic response for a smoking cessation medication when considering short-term outcomes. Importantly, this is also the first demonstration that women have similar rates of quitting to men when considering longer-term, 1-year outcomes.
Source: Nicotine and Tobacco Research - Category: Addiction Authors: McKee, S. A., Smith, P. H., Kaufman, M., Mazure, C. M., Weinberger, A. H. Tags: Original Investigation Source Type: research
More News: Addiction | Bupropion | Chantix | Clinical Trials | Nicotine | Smokers | Study | Wellbutrin | Women